236 related articles for article (PubMed ID: 34046363)
21. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
[TBL] [Abstract][Full Text] [Related]
22. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
[TBL] [Abstract][Full Text] [Related]
23. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Nikolaou A; Ambavane A; Shah A; Ma W; Tosh J; Kapetanakis V; Willson J; Wang F; Hogea C; Gorsh B; Gutierrez B; Sapra S; Suvannasankha A; Samyshkin Y
Expert Rev Hematol; 2021 Dec; 14(12):1137-1145. PubMed ID: 34465265
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.
Collins J; van Noort M; Rathi C; Post TM; Struemper H; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1411-1424. PubMed ID: 37465991
[TBL] [Abstract][Full Text] [Related]
25. Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging.
Mencucci R; Cennamo M; Alonzo L; Senni C; Vagge A; Ferro Desideri L; Scorcia V; Giannaccare G
J Clin Med; 2022 May; 11(10):. PubMed ID: 35629012
[TBL] [Abstract][Full Text] [Related]
26. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
27. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
[TBL] [Abstract][Full Text] [Related]
28. Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.
Matsumiya W; Karaca I; Ghoraba H; Akhavanrezayat A; Mobasserian A; Hassan M; Regenold J; Yasar C; Liedtke M; Kitazawa K; Nguyen QD
Am J Ophthalmol Case Rep; 2021 Sep; 23():101133. PubMed ID: 34169181
[TBL] [Abstract][Full Text] [Related]
29. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study.
Terpos E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Spiliopoulou V; Kostopoulos IV; Syrigou RE; Eleutherakis-Papaiakovou E; Gkolfinopoulos S; Tsitsilonis OE; Kastritis E; Dimopoulos MA
Haematologica; 2024 Feb; ():. PubMed ID: 38356458
[TBL] [Abstract][Full Text] [Related]
30. Belantamab mafodotin for the treatment of multiple myeloma.
Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
[TBL] [Abstract][Full Text] [Related]
32. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
Alegre A; Benzo G; Alonso R; Martínez-López J; Jimenez-Ubieto A; Cuéllar C; Askari E; Prieto E; Aláez C; Aguado B; Velasco A; Krsnik I; Bocanegra A; Llorente L; Muñoz-Linares C; Morales A; Giménez E; Iglesias R; Martínez-Chamorro C; Alonso A; Jiménez-Montes C; Blanchard MJ;
Oncol Ther; 2023 Mar; 11(1):83-96. PubMed ID: 36509945
[TBL] [Abstract][Full Text] [Related]
33. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
Sheikh S; Lebel E; Trudel S
Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
[TBL] [Abstract][Full Text] [Related]
34. Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City.
Jaber W; Abdaljalil A; Ali A; Abu Haleeqa M; Mheidly K
Cureus; 2023 Aug; 15(8):e44433. PubMed ID: 37791224
[TBL] [Abstract][Full Text] [Related]
35. Corneal epithelial changes in a patient treated with belantamab mafodotin.
Inferrera L; Giglio R; Tognetto D
Taiwan J Ophthalmol; 2023; 13(3):380-383. PubMed ID: 38089508
[TBL] [Abstract][Full Text] [Related]
36. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
[TBL] [Abstract][Full Text] [Related]
37. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
[TBL] [Abstract][Full Text] [Related]
38. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
[TBL] [Abstract][Full Text] [Related]
39. Belantamab Mafodotin: First Approval.
Markham A
Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
[TBL] [Abstract][Full Text] [Related]
40. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
Condorelli A; Garibaldi B; Gagliano C; Romano A; Del Fabro V; Parrinello NL; Longo A; Cosentino S; Di Raimondo F; Conticello C
Acta Haematol; 2021 Nov; ():. PubMed ID: 34839282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
